GlassScriptPhysician profile
Stacey D Knapp
NPI 1104826569
$6,637.32
in general payments reported to CMS, 2019-2025
38 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.58 · 2022: $1,829 · 2023: $1,750 · 2024: $1,851 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,657 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,656.93 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $791.53 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $688.32 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $588.73 | 2022-2025 | |
| Abbvie INC. | $531.87 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $523.38 | 2022-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Glaxosmithkline, LLC. | $519.51 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $466.16 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $361.89 | 2022-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $345.66 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.85 | 2021-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $169.03 | 2021-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $153.41 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $129.72 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.12 | 2022-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $89.60 | 2023-2025 | Gemtesa |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $89.47 | 2022-2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $83.53 | 2022 | |
| Exact Sciences Corporation | $80.05 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $64.15 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $60.92 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $55.20 | 2024-2025 | Repatha, Otezla, Otezla |
| Organon LLC | $51.85 | 2025 | Nexplanon |
| Sunovion Pharmaceuticals INC. | $44.94 | 2022 | |
| Insulet Corporation | $43.77 | 2023-2025 | Omnipod |
| Lundbeck LLC | $41.25 | 2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $40.23 | 2023 | |
| Aimmune Therapeutics, INC. | $33.21 | 2024-2025 | Zenpep |
| Ultragenyx Pharmaceutical INC. | $27.60 | 2022-2023 | |
| Harmony Biosciences LLC | $26.93 | 2024 | |
| Edwards Lifesciences Corporation | $23.94 | 2023 | |
| Hologic Sales and Service, LLC | $22.54 | 2022 | |
| Nevro Corp. | $20.27 | 2023 | Senza |
| Antares Pharma, INC. | $19.44 | 2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.26 | 2025 | Caplyta |
| Gilead Sciences, INC. | $13.63 | 2023 | |
| Currax Pharmaceuticals LLC | $13.15 | 2024 | Onzetra Xsail, Contrave |
| Novartis Pharmaceuticals Corporation | $12.19 | 2022 | |
| Genentech USA, INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.